According to the UK SmPC, these include: Nausea (very common, affecting more than 1 in 10 patients) Diarrhoea and constipation (very common) Vomiting and abdominal pain (common) Decreased appetite and dyspepsia (common) These symptoms are generally mild to moderate in severity and tend to diminish over time as the body adjusts to the medication
Mais en les neutralisant, lorganisme sassure une bonne protection contre divers maux
Spiering BA, Kraemer WJ, Vingren JL, Hatfield DL, Fragala MS, Ho JY, Maresh CM, Anderson JM, Volek JS
It is important to remember that for most people, these sensations are temporary and manageable
Further optimization has been explored through exosome preconditioning
These findings were consistent in the per-protocol analysis (estimated mean difference [95% CI] for dulaglutide versus placebo 492 mL [811, 173]) and in the sensitivity analyses adjusting for adverse effects at the beginning of the evaluation visit (474 mL [812, 136]) or anytime during the evaluation visit (428 mL [850, 6])
